DNA hypermethylation as a predictor of PSA recurrence in patients with low- and intermediate-grade prostate cancer

Anticancer Research

Volumn 33, Issue 12, 2013, Pages 5249-5254

  Moritz, Rudolf ^a,b   Ellinger, Jörg ^b   Nuhn, Philipp ^d   Haese, Alexander ^c   Müller, Stefan C ^b   Graefen, Markus ^c   Schlomm, Thorsten ^c   Bastian, Patrick J ^e  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c UNIVERSITY OF HAMBURG   (Germany)

^d UNIVERSITY OF MUNICH   (Germany)

^e Golzheim Paracelsus Clinic   (Germany)

Author keywords

DNA hypermethylation; Methylation; Prognosis; Prostate cancer; PTGS2; RARB

Indexed keywords

APC PROTEIN; DNA; GLUTATHIONE TRANSFERASE P1; PROSTAGLANDIN ENDOPEROXIDE SYNTHASE 2; PROSTAGLANDIN SYNTHASE; PROSTATE SPECIFIC ANTIGEN; PROTEIN; RETINOIC ACID RECEPTOR BETA; TAZAROTENE INDUCED GENE 1 PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER RECURRENCE; CPG ISLAND; DNA METHYLATION; GENE LOCUS; GLEASON SCORE; HUMAN; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PREDICTION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; QUANTITATIVE ANALYSIS; SEMINAL VESICLE;

EID: 84891428389     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics 2012. CA Cancer J Clin 62: 10-29, 2012.
2. Draisma G, Boer R, Otto SJ, van der Cruijsen IW, Damhuis RA, Schroeder FH and de Koning: Lead times and overdetection due to prostate-specific antigen screening: Estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 95: 868-878, 2003.
3. Raaijmakers R, Wildhagen MF, Ito K, Pàez A, de Vries SH, Roobol MJ and Schroeder FH: Prostate-specific antigen change in the European Randomized Study of Screning for Prostate Cancer, section Rotterdam. Urology 63(2): 316-320, 2004.
4. Dobosy JR, Roberts JLW, Fu VX and Jarrard DF: The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostates hyperplasia. J Urol 177: 822-831, 2007.
5. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC and Partin AW: Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 249 (4): 433-439, 2005.
6. Helpap B and Evegad L: The value of the modified Gleason grading system of prostate adenocarcinoma in routine urological diagnostics. UrologeA 46(1): 59-62, 2007.
7. Boerno ST, Fischer A, Kerick M, Laible M, Brase JC, Kuner R, Dahl A, Grimm C, Sayanjali B, Isau M, Roehr C, Wunderlich A, Timmermann B, Claus R, Plass C, Graefen M, Simon R, Demichelis F, Rubin MA, Sauter G, SchlommT, Sueltmann H, Lehrach H and Schweiger MR: Genome-wide DNA methylation events in TMPRSS2-ERG fusion-negative prostate cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylation. Cancer Discov 11: 1024-1035, 2012.
8. Weischenfeldt J, Simon R, Feuerbach L, Schlangen K, Weichenhan D, Minner S, Wuttig D, Warnatz HJ, Stehr H, Rausch T, Jäger N, Gu L, Bogatyrova O, Stuetz AM, Claus R, Elis J, Gerhaeuser C, Huang PH, Hutter B, Kabbe R, Lawerenz C, Radomski S, Bartholomae CC, Faelth M, Gade S, Schmidt M, Amschuler N, Haß T, Galal R, Gjoni J, Kuner R, Baer C, Masser S, von Kalle C, Zichner T, Benes V, Raeder B, Mader M, Amstislavskiy V, Avci M, Lehrach H, Parkhomchuk D, Sultan M, Burkhardt L, Graefen M, Huland H, Kluth M, Krohn A, Sirma L, Steurer S, Grupp K, Sueltmann H, Sauter G, Plass C, Brors C, Yaspo ML, Korbel JO and Schlomm T: Integrative genomic analyses reveal androgen-driven somatic alteration landscape in early-onset prostate cancer. Cancer Cell 23(2): 159-170, 2012.
9. Enokida H, Shiina H, Urakami S, Igawa M, Ogishima T, Li LC, Kawahara M, Nakagawa M, Kane CJ, Carroll PR and Dahiya R: Multigene methylation analysis for detection and staging of prostate cancer. Clin Cancer Res 11: 6582-6588, 2005.
10. Lodygin D, Epanchintsev A, Menssen A, Diebold J and Hermeking H: Functional epigenomics identifies genes frequently silenced in prostate cancer. Cancer Res 65: 4218-4227, 2005.
11. Yegnasubramanian S, Kowalski J, Gonzalgo ML, Zahurak M, Piantadosi S, Walsh PC, de Marzo AM, Isaacs WB and Nelson WG: Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 64: 1975-1986, 2004.
12. Ellinger J, Bastian PJ, Jurgan T, Biermann K, Kahl P, Heukamp LC, Wernert N, Mueller SC and von Ruecker A: CpG island hypermethylation at multiple gene sites in the diagnosis and prognosis of prostate cancer. Urology 71(1): 161-167, 2008.
13. Bastian PJ, Yegnasubramanian S, Palapattu GS, Rogers CG, Lin X, De Marzo AM and Nelson WG: Molecular biomarker in prostate cancer: The role of CpG island hypermethylation. Eur Urol 46: 698-708, 2004.
14. Woodson K, Gillespie J, Hanson J, Emmert-Buck M, Phillips JM, Linehan WM and Tangrea JA: Heterogenous gene methylation patterns among pre-invasive and cancerous lesions of the prostate: A histopathologic study of whole mount prostate specimens. Prostate 60(1): 25-31, 2004.
15. Alumkal JJ, Zhang Z, Humphreys EB, Bennett C, Mangold LA, Carducci MA, Partin AW, Garrett-Mayer E, De Marzo AM and Herman JG: Effect of DNA methylation on identification of aggressive prostate cancer. Urology 72(6): 1234-1239, 2008.
16. Singal R, Ferdinand L, Reis IM and Schlesselmann JJ: Methylation of multiple genes in prostate cancer and the relationship with clinicopathological features of disease. Oncol Rep 12(3): 631-637, 2004.
17. Bastian PJ, Ellinger J, Wellmann A, Wernert N, Heukamp LC, Mueller SC and von Ruecker A: Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci. Clin Cancer Res 11(11): 4037-4043, 2005.
18. Maruyama R, Toyooka S, Toyooka KO, Virmani AK, Zöchbauer-Mueller S, Farinas AJ, Minna JD, McConnell J, Frenkel EP and Gazdar AF: Aberrant promotermethylation profile of prostate cancers and its relationship to clinicopathological features. Clin Cancer Res 8(2): 514-519, 2002.
19. Tokumaru Y, Harden SV, Sun DI, Yamashita K, Epstein JI and Sidransky D: Optimal use of panel of methylation markers with GSTP1 hypermethylation in the diagnosis of prostate adenocarcinoma. Clin Cancer Res 10(16): 5518-5522, 2004.
20. Kang GH, Lee S, Lee HJ and Hwang KS: Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia. J Pathol 202(2): 233-240, 2004.
21. Woodson K, Hanson J and Tangrea J: A survey of gene-specific methylation in human prostate cancer among black and white men. Cancer Lett 205(2): 181-188, 2004.
22. Jéronimo C, Henrique R, Hoque MO, Ribeiro FR, Oliveira J, Fonseca D, Teixeira MR, Lopes C and Sidransky D: Quantitative RARB2 hypermethylation: A promising prostate cancer marker. Clin Cancer Res 10: 4010-4014, 2004.
23. Bastian PJ, Ellinger J, Heukamp LC, Kahl P, Mueller SC and von Ruecker A: Prognostic value of CpG island hypermethylation at PTGS2, RARB, EDNRB, and other gene loci in patients undergoing radical prostatectomy. Eur Urol 51(3): 665-674, 2007.
24. Lehmann U, Langer F, Feist H, Gloeckner S, Hasemeier B and Kreipe H: Quantitative assessment of promotor hypermethylation during breast cancer development. Am J Pathol 160(2): 605-612, 2002.
25. Suzuki M, Shigematsu H, Shivapurkar N, Reddy J, Miyajima K, Takahashi T, Gazdar AF and Frenkel EP: Methylation of apoptosis related genes in the pathogenesis and prognosis of prostate cancer. Cancer Lett 242(2): 222-230, 2006.
26. Wang W, Bergh A and Damber JE: Cyclo-oxygenase-2 expression correlates with local chronic inflammation and tumor neovascularization in human prostate cancer. Clin Cancer Res 11(9): 3250-3256, 2005.
27. Sirchia SM, Ren M, Pili R, Sironi E, Somenzi G, Ghidoni R, Toma S, Nicolò G and Sacchi N: Endogenous reactivation of the RARB2 tumor suppressor gene epigenetically silenced in breast cancer. Cancer Res 62(9): 2455-2461, 2002.
28. Woodson K, Hanson J and Tangrea J: A survey of gene-specific methylation in human prostate cancer among black and white men. Cancer Lett 205(2): 181-188, 2004.
29. Ellinger J, Haan K, Heukamp LC, Kahl P, Buettner R, Mueller SC, von Ruecker A and Bastian PJ: CpG island hypermethylation in cell-free serum DNA identifies patients with localized prostate cancer. Prostate 68(1): 42-49, 2008.
30. Ellinger J, Mueller SC, Stadler TC, Jung A, von Ruecker A and Bastian PJ: The role of cell-free circulating DNA in the diagnosis and prognosis of prostate cancer. Urol Oncol 29(2): 124-129, 2009.